EP
VKTX icon

Eversept Partners’s Viking Therapeutics VKTX Stock Holding History

Eversept Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.5M Buy
602,922
+363,812
+152% +$11.8M 1.22% 22
2026
Q1 		$7.78M Buy
+239,110
New +$7.69M 0.41% 49
2024
Q3 		– Sell
-138,489
Closed -$7.34M – 81
2024
Q2 		$7.34M Buy
138,489
+115,671
+507% +$7.58M 0.5% 35
2024
Q1 		$1.87M Buy
+22,818
New +$1.02M 0.12% 62
2018
Q4 		– Sell
-25,000
Closed -$436K – 65
2018
Q3 		$436K Buy
+25,000
New +$298K 0.19% 55

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Eversept Partners's VKTX Position: Q2 2026 in Review

Eversept Partners increased its Viking Therapeutics (VKTX) stake by 152% in Q2 2026, buying an estimated $11.8M and bringing the position to 602,922 shares worth $23.5M. The position accounts for 1.22% of the portfolio, ranked #22.

Eversept Partners first reported a position in VKTX in Q3 2018 and has held it in 5 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Eversept Partners held 602,922 shares of Viking Therapeutics worth $23.5M as of Q2 2026.
  • Eversept Partners bought 363,812 Viking Therapeutics shares in Q2 2026, an estimated $11.8M.
  • Viking Therapeutics made up 1.22% of Eversept Partners's portfolio in Q2 2026, its #22 holding.
  • Eversept Partners first reported a position in Viking Therapeutics in Q3 2018 and has held it in 5 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.